SIWA Therapeutics Takes a Key Step Forward in Novel Efforts to Treat Cancer by Removing Senescent Cells Announces Humanization of Anti-Aging Antibody that Inhibits Tumor Metastasis Chicago, IL, May 18, 2017 – Biotechnology innovator SIWA Therapeutics announced that it has successfully humanized its SIWA 318 monoclonal antibody, a significant milestone in the race to treat cancer and numerous other diseases by removing senescent cells, which become increasingly problematic as humans age. Senescent cells lose their ability to divide or replicate for a variety of reasons and also secrete chemicals which interfere with the normal functions of other cells as well as contribute to inflammation. When too many senescent cells accumulate, they can cause or exacerbate a variety of age-related and degenerative diseases including arthritis, ALS, Alzheimer’s, Parkinson’s, heart disease and…
